Compare Stocks

→ REVEALED: Elon Musk’s Secret A.I. Facility? (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLSD Clearside Biomedical	$1.29 +3.2%	$1.46	$0.65 ▼ $2.12	$93.40M	2.29	357,823 shs	184,217 shs
CYAD Celyad Oncology	$0.60	$0.67	$0.46 ▼ $3.07	N/A	N/A	N/A	3,009 shs
MLND Millendo Therapeutics	$3.34 -7.0%	$4.00	$0.92 ▼ $16.95	$63.60M	0.48	1.52 million shs	586,820 shs
NBSE NeuBase Therapeutics	$0.42 -4.6%	$0.72	$0.39 ▼ $5.40	$1.65M	0.83	229,926 shs	34,974 shs
OTIC Otonomy	$0.01	$0.06	$0.01 ▼ $2.54	$582K	1.54	937,525 shs	N/A

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLSD Clearside Biomedical	+3.20%	0.00%	-24.56%	-10.42%	+17.27%
CYAD Celyad Oncology	0.00%	0.00%	0.00%	0.00%	-27.27%
MLND Millendo Therapeutics	-6.96%	-10.22%	-8.24%	-21.04%	+13.22%
NBSE NeuBase Therapeutics	-4.90%	+2.39%	-56.95%	-30.58%	-87.58%
OTIC Otonomy	0.00%	0.00%	0.00%	0.00%	0.00%

Forget Nvidia, buy this A.I. Stock Now (Ad)

Forget Nvidia, Microsoft or Google. Our tech expert and venture capitalist Luke Lango believes this is Elon Musk’s favorite A.I. stock. Why? Because this company is supplying Elon Musk with a key piece of advanced tech for his new A.I. venture.

Click here to see the details.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLSD Clearside Biomedical	3.1788 of 5 stars	3.5	5.0	0.0	0.0	3.3	1.7	0.6
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	0.9623 of 5 stars	0.0	3.0	0.0	4.7	1.9	0.8	0.6
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLSD Clearside Biomedical	3.00	Buy	$4.75	268.22% Upside
CYAD Celyad Oncology	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A

Current Analyst Ratings

Latest MLND, CLSD, OTIC, CYAD, and NBSE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/11/2024	CLSD Clearside Biomedical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00
3/14/2024	CLSD Clearside Biomedical	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00
3/13/2024	CLSD Clearside Biomedical	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$5.00
3/13/2024	CLSD Clearside Biomedical	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$5.00 ➝ $4.00

(Data available from 4/16/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLSD Clearside Biomedical	$8.23M	11.71	N/A	N/A	($0.25) per share	-5.16
CYAD Celyad Oncology	$110K	144.65	N/A	N/A	$0.20 per share	3.00
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	$1.78 per share	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	$11.04 per share	N/A
OTIC Otonomy	$130K	4.48	N/A	N/A	$0.97 per share	0.01

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLSD Clearside Biomedical	-$32.49M	-$0.53	N/A	N/A	N/A	-394.91%	N/A	-85.31%	5/9/2024 (Estimated)
CYAD Celyad Oncology	-$9.14M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	-$36.41M	N/A	0.00	∞	N/A	N/A	-91.03%	-72.44%	N/A
NBSE NeuBase Therapeutics	-$4.37M	-$7.70	N/A	∞	N/A	N/A	-99.74%	-60.13%	5/9/2024 (Estimated)
OTIC Otonomy	-$51.18M	-$0.77	N/A	∞	N/A	N/A	-137.86%	-68.50%	N/A

Latest MLND, CLSD, OTIC, CYAD, and NBSE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
3/12/2024	Q4 2023	CLSD Clearside Biomedical	-$0.10	-$0.08	+$0.02	-$0.08	$3.40 million	$6.35 million

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLSD Clearside Biomedical	N/A	N/A	N/A	N/A	N/A
CYAD Celyad Oncology	N/A	N/A	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	N/A	N/A	N/A	N/A
NBSE NeuBase Therapeutics	N/A	N/A	N/A	N/A	N/A
OTIC Otonomy	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLSD Clearside Biomedical	N/A	4.42	4.42
CYAD Celyad Oncology	N/A	N/A	N/A
MLND Millendo Therapeutics	N/A	6.39	6.39
NBSE NeuBase Therapeutics	N/A	2.87	2.87
OTIC Otonomy	N/A	1.74	1.74

Ownership

Institutional Ownership

Company	Institutional Ownership
CLSD Clearside Biomedical	18.75%
CYAD Celyad Oncology	N/A
MLND Millendo Therapeutics	N/A
NBSE NeuBase Therapeutics	12.37%
OTIC Otonomy	41.23%

Insider Ownership

Company	Insider Ownership
CLSD Clearside Biomedical	9.80%
CYAD Celyad Oncology	0.94%
MLND Millendo Therapeutics	N/A
NBSE NeuBase Therapeutics	13.90%
OTIC Otonomy	1.09%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
CLSD Clearside Biomedical	30	74.72 million	67.40 million	Optionable
CYAD Celyad Oncology	95	26.52 million	26.28 million	Not Optionable
MLND Millendo Therapeutics	12	19.04 million	N/A	Not Optionable
NBSE NeuBase Therapeutics	37	3.75 million	3.23 million	Not Optionable
OTIC Otonomy	51	68.53 million	67.78 million	Optionable

MLND, CLSD, OTIC, CYAD, and NBSE Headlines

Source	Headline
	Allergic Contact Dermatitis and Topical Antibiotics medscape.com - September 10 at 4:13 PM
	Hearing Loss in Adults nejm.org - August 21 at 11:30 PM
	Research Publications slu.edu - August 4 at 7:44 PM
	Management of Pediatric Otitis Media medscape.com - May 11 at 11:26 PM
	Hearing Loss Pipeline Analysis Demonstrates 35+ Key Companies at the Horizon Expected to Transform the Treatme - openPR news.google.com - May 8 at 10:11 AM
	Alluvial Capital Management Q1 2023 Letter To Partners - Seeking Alpha news.google.com - April 28 at 7:44 AM
	Vertigo Treatments Market Forecast: Analysis and Insights for 2023 ... - Digital Journal news.google.com - April 27 at 9:58 AM
	Hearing Loss Clinical Trial Pipeline Insights Featuring 32+ Companies - openPR news.google.com - April 25 at 4:57 PM
	ENT Disorder Treatment Market to grow at a CAGR of over 3.3 ... - Digital Journal news.google.com - April 24 at 7:52 AM
	Hearing Loss Clinical Trials 2023 (Updates): FDA Approvals ... - Digital Journal news.google.com - April 11 at 10:37 PM
	ENT Disorder Treatment Market : Factors Benefitting Emergence of ... - Digital Journal news.google.com - April 10 at 7:51 AM
	[Research Report] Hearing Loss Disease Treatment Market Improve ... - Digital Journal news.google.com - April 10 at 7:51 AM
	Hearing Loss Emerging and Marketed Drugs Assessment (2023 ... - Digital Journal news.google.com - April 3 at 7:09 PM
	Hearing-focused biotech grabs trio of programs from Otonomy's fire ... - Endpoints News news.google.com - March 30 at 1:22 PM
	Alector cuts 11% of workforce as it doubles down on late-stage ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Mathai Mammen hands in J&J's R&D keys to lead Greg Verdine's ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Boehringer reports robust sales led by type 2 diabetes and ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Seelos Therapeutics 'temporarily' stops study in rare neuro disorder ... - Endpoints News news.google.com - March 30 at 8:21 AM
	Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear Disorders Pipeline and Appoints Industry Leaders to ... - PR Newswire news.google.com - March 29 at 8:47 PM
	Spiral Therapeutics Acquires Otonomy Assets to Boost Inner Ear ... - BioSpace news.google.com - March 29 at 10:46 AM
	Otic Drug Market Size Historical Growth, Analysis, Opportunities and Forecast To 2029\| Pediapharm Novus Therap - openPR news.google.com - March 27 at 9:52 AM
	Hearing Loss Pipeline Drugs and Companies Insight Report, 2023 ... - Digital Journal news.google.com - March 23 at 9:50 AM
	Hearing Loss Disease Treatment Market 2023 key developmental ... - openPR news.google.com - March 22 at 6:46 PM
	Hearing Loss Disease Treatment Market 2023 key developmental strategies implemented by the key players till 20 - openPR news.google.com - March 21 at 9:36 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

3 Value Stocks Too Small For Buffett’s Portfolio
March 28, 2024 12:16 PM
View 3 Value Stocks Too Small For Buffett’s Portfolio
Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
April 2, 2024 9:15 AM
View Canoo, Inc. Bites the Dust: Mullen Automotive Is a Better Bet
UiPath Cuts Q1 and Raises Full Year Guidance
March 26, 2024 7:41 AM
View UiPath Cuts Q1 and Raises Full Year Guidance
Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
April 10, 2024 7:55 AM
View Can Tyson Win from Repealing Its No-Antibiotic Chicken Pledge?
3 Computer Vision Stocks for Long-Term Gains From AI
April 16, 2024 6:08 AM
View 3 Computer Vision Stocks for Long-Term Gains From AI

All Headlines

Company Descriptions

Clearside Biomedical

NASDAQ:CLSD

Clearside Biomedical, Inc., a biopharmaceutical company, focuses on the revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space. It offers XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of uveitis macular edema. It also develops CLS-AX, an axitinib injectable suspension for suprachoroidal injection, which is in Phase IIb clinical trial to treat wet AMD. The company has a collaboration with Bausch Health, Arctic Vision, REGENXBIO, Inc., BioCryst Pharmaceuticals, Inc., and Aura Biosciences. Clearside Biomedical, Inc. was incorporated in 2011 and is headquartered in Alpharetta, Georgia.

Celyad Oncology

NASDAQ:CYAD

Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.

Millendo Therapeutics

NASDAQ:MLND

As of June 25, 2021, Millendo Therapeutics, Inc. was acquired by Tempest Therapeutics Inc., in a reverse merger transaction. Millendo Therapeutics, Inc. operates as a biopharmaceutical company. The company is headquartered in Ann Arbor, Michigan.

NeuBase Therapeutics

NASDAQ:NBSE

NeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.

Otonomy

NASDAQ:OTIC

Otonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm's product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial